Carlisle Companies Incorporated (CSL)

Return on equity (ROE)

Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income US$ in thousands 1,311,800 767,400 924,000 421,700 320,100
Total stockholders’ equity US$ in thousands 2,463,300 2,829,000 3,024,400 2,629,500 2,537,700
ROE 53.25% 27.13% 30.55% 16.04% 12.61%

December 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $1,311,800K ÷ $2,463,300K
= 53.25%

Carlisle Companies Incorporated has experienced a notable upward trend in return on equity (ROE) over the past five years. The ROE increased from 12.61% as of December 31, 2020, to 53.25% as of December 31, 2024, showcasing a significant improvement in the company's ability to generate profits from shareholders' equity.

This steady increase in ROE reflects positively on Carlisle's operational efficiency and profitability. It suggests that the company is effectively utilizing its equity to generate higher returns for its investors. The notable surge in ROE from 2020 to 2024 indicates improved financial performance and enhanced shareholder value creation over the period.

The ROE of 30.55% as of December 31, 2022, and 27.13% as of December 31, 2023, also demonstrate continued strength in the company's financial performance and its ability to deliver solid returns to equity investors. Overall, the increasing trend in ROE for Carlisle Companies Incorporated reflects positively on the company's financial health and operational effectiveness, indicating a favorable position for stakeholders.


Peer comparison

Dec 31, 2024

Company name
Symbol
ROE
Carlisle Companies Incorporated
CSL
53.25%
West Pharmaceutical Services Inc
WST
18.37%